<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37048104</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Regulation of the Innate Immune System as a Therapeutic Approach to Supporting Respiratory Function in ALS.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1031</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12071031</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a clinical diagnosis used to define a neurodegenerative process that involves progressive loss of voluntary muscle function and leads to death within 2-5 years after diagnosis, in most cases because of respiratory function failure. Respiratory vital capacity (VC) measurements are reproducible and strong predictors of survival. To understand the role of the innate immune response in progressive VC loss we evaluated ALS clinical trial and biomarker results from a 6-month phase 2 study of NP001, a regulator of innate immune function. All ALS baseline values were similar between treated and controls except for those &gt; 65 years old who were excluded from analysis. Treated patients with plasma CRP &#x2265; 1.13 mg/L (high CRP) showed a 64% slower rate of VC decline compared with placebo and those with plasma CRP &lt; 1.13 mg/L (low CRP) who showed no response. High CRP patients showed no age associated loss of VC whereas low CRP patients showed an age dependent loss of VC function. Plasma levels of serum amyloid A (SAA) were similarly elevated in high CRP patients consistent with ongoing innate immune activation. Plasma TGFB1 in high CRP treated patients was 95% higher than placebo at 6-months, confirming the activation and release of this anti-inflammatory factor by the innate immune alpha 2 macroglobulin (A2M) system. This report is the first to link a biomarker confirmed regulation of the innate immune system with a therapeutic approach for controlling VC loss in ALS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-7232-2602</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuvivo, Inc., Palo Alto, CA 94301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rongzhen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bracci</LastName><ForeName>Paige M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azhir</LastName><ForeName>Ari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuvivo, Inc., Palo Alto, CA 94301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Bruce D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Neuvivo, Inc., Palo Alto, CA 94301, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hudson Innovations, LLC, Nyack, NY 10960, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012119" MajorTopicYN="N">Respiration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A2M</Keyword><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CRP</Keyword><Keyword MajorTopicYN="N">NP001</Keyword><Keyword MajorTopicYN="N">SAA</Keyword><Keyword MajorTopicYN="N">TGFB1</Keyword><Keyword MajorTopicYN="N">VC</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">macrophage</Keyword></KeywordList><CoiStatement>Zhang, R. reports no conflict of interest. Bracci, P.M. and Forrest, B.D. are consultants for Neuvivo, Inc. Azhir, A. and McGrath, M.S. are the founders of Neuvivo, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37048104</ArticleId><ArticleId IdType="pmc">PMC10093136</ArticleId><ArticleId IdType="doi">10.3390/cells12071031</ArticleId><ArticleId IdType="pii">cells12071031</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman E.L., Goutman S.A., Petri S., Mazzini L., Savelieff M.G., Shaw P.J., Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022;400:1363&#x2013;1380. doi: 10.1016/S0140-6736(22)01272-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId><ArticleId IdType="pmc">PMC10089700</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews J.A., Meng L., Kulke S.F., Rudnicki S.A., Wolff A.A., Bozik M.E., Malik F.I., Shefner J.M. Association between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients with Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018;75:58&#x2013;64. doi: 10.1001/jamaneurol.2017.3339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.3339</ArticleId><ArticleId IdType="pmc">PMC5833488</ArticleId><ArticleId IdType="pubmed">29181534</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A., Zaidi S., Iltis C., Ribon M., Berriat F., Schiaffino L., Jolly A., de la Grange P., Mallat M., Bohl D., et al. Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat. Neurosci. 2020;23:1339&#x2013;1351. doi: 10.1038/s41593-020-00718-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00718-z</ArticleId><ArticleId IdType="pubmed">33077946</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiraishi W., Yamasaki R., Hashimoto Y., Ko S., Kobayakawa Y., Isobe N., Matsushita T., Kira J.-I. Clearance of peripheral nerve misfolded mutant protein by infiltrated macrophages correlates with motor neuron disease progression. Sci. Rep. 2021;11:16438. doi: 10.1038/s41598-021-96064-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-96064-6</ArticleId><ArticleId IdType="pmc">PMC8360983</ArticleId><ArticleId IdType="pubmed">34385589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Hadlock K.G., Do H., Yu S., Honrada R., Champion S., Forshew D., Madison C., Katz J., Miller R.G., et al. Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS) J. Neuroimmunol. 2011;230:114&#x2013;123. doi: 10.1016/j.jneuroim.2010.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.08.012</ArticleId><ArticleId IdType="pmc">PMC3448551</ArticleId><ArticleId IdType="pubmed">20884065</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Dupre N., Petri S., Strong M., Kriz J., Julien J.-P. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J. Exp. Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Zhao W., Neal D.W., Thonhoff J.R., Thome A.D., Faridar A., Wen S., Wang J., Appel S.H. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci. Rep. 2020;10:15295. doi: 10.1038/s41598-020-72247-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72247-5</ArticleId><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil R.H., Al-Humadi N. Types of acute phase reactants and their importance in vaccination. Biomed. Rep. 2020;12:143&#x2013;152. doi: 10.3892/br.2020.1276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2020.1276</ArticleId><ArticleId IdType="pmc">PMC7054702</ArticleId><ArticleId IdType="pubmed">32190302</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashist S.K., Venkatesh A.G., Marion Schneider E., Beaudoin C., Luppa P.B., Luong J.H. Bioanalytical advances in assays for C-reactive protein. Biotechnol. Adv. 2016;34:272&#x2013;290. doi: 10.1016/j.biotechadv.2015.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2015.12.010</ArticleId><ArticleId IdType="pubmed">26717866</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak A., Agrawal A. Evolution of C-Reactive Protein. Front. Immunol. 2019;10:943. doi: 10.3389/fimmu.2019.00943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00943</ArticleId><ArticleId IdType="pmc">PMC6503050</ArticleId><ArticleId IdType="pubmed">31114584</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproston N.R., Ashworth J.J. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front. Immunol. 2018;9:754. doi: 10.3389/fimmu.2018.00754.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00754</ArticleId><ArticleId IdType="pmc">PMC5908901</ArticleId><ArticleId IdType="pubmed">29706967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngwa D.N., Agrawal A. Structure-Function Relationships of C-Reactive Protein in Bacterial Infection. Front. Immunol. 2019;10:166. doi: 10.3389/fimmu.2019.00166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00166</ArticleId><ArticleId IdType="pmc">PMC6400226</ArticleId><ArticleId IdType="pubmed">30863393</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez R.V., Kuznetsova V., Connelly A.N., Hel Z., Szalai A.J. C-Reactive Protein Promotes the Expansion of Myeloid Derived Cells with Suppressor Functions. Front. Immunol. 2019;10:2183. doi: 10.3389/fimmu.2019.02183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02183</ArticleId><ArticleId IdType="pmc">PMC6759522</ArticleId><ArticleId IdType="pubmed">31620123</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones N.R., Pegues M.A., McCrory M.A., Kerr S.W., Jiang H., Sellati R., Berger V., Villalona J., Parikh R., McFarland M., et al. Collagen-induced arthritis is exacerbated in C-reactive protein-deficient mice. Arthritis Rheum. 2011;63:2641&#x2013;2650. doi: 10.1002/art.30444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30444</ArticleId><ArticleId IdType="pmc">PMC3168703</ArticleId><ArticleId IdType="pubmed">21567377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.Y., Tang Z.M., Wang Z., Lv J.M., Liu X.L., Liang Y.L., Cheng B., Gao N., Ji S.-R., Wu Y. C-Reactive Protein Protects Against Acetaminophen-Induced Liver Injury by Preventing Complement Overactivation. Cell. Mol. Gastroenterol. Hepatol. 2022;13:289&#x2013;307. doi: 10.1016/j.jcmgh.2021.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2021.09.003</ArticleId><ArticleId IdType="pmc">PMC8599171</ArticleId><ArticleId IdType="pubmed">34536564</ArticleId></ArticleIdList></Reference><Reference><Citation>Teupser D., Weber O., Rao T.N., Sass K., Thiery J., Fehling H.J. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J. Biol. Chem. 2011;286:6272&#x2013;6279. doi: 10.1074/jbc.M110.161414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.161414</ArticleId><ArticleId IdType="pmc">PMC3057833</ArticleId><ArticleId IdType="pubmed">21149301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.H., Gona P., Sutherland P.A., Benjamin E.J., Wilson P.W., Larson M.G., Vasan R.S., Robins S.J. Long-term C-reactive protein variability and prediction of metabolic risk. Am. J. Med. 2009;122:53&#x2013;61. doi: 10.1016/j.amjmed.2008.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2008.08.023</ArticleId><ArticleId IdType="pmc">PMC2654380</ArticleId><ArticleId IdType="pubmed">19114172</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M., Qiu S., He Y., Li L., Wu T., Ding N., Li F., Zhao A.Z., Yang G. Genetic ablation of C-reactive protein gene confers resistance to obesity and insulin resistance in rats. Diabetologia. 2021;64:1169&#x2013;1183. doi: 10.1007/s00125-021-05384-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-021-05384-9</ArticleId><ArticleId IdType="pubmed">33544171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharel S., Ojha R., Preethish-Kumar V., Bhagat R. C-reactive protein levels in patients with amyotrophic lateral sclerosis: A systematic review. Brain Behav. 2022;12:e2532. doi: 10.1002/brb3.2532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.2532</ArticleId><ArticleId IdType="pmc">PMC8933772</ArticleId><ArticleId IdType="pubmed">35201675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Li M., Zhang J., Huang X. Association Between C-Reactive Protein and Risk of Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. Front. Genet. 2022;13:919031. doi: 10.3389/fgene.2022.919031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.919031</ArticleId><ArticleId IdType="pmc">PMC9164009</ArticleId><ArticleId IdType="pubmed">35669191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng N., Liang Y., Du X., Ye R.D. Serum amyloid A promotes LPS clearance and suppresses LPS-induced inflammation and tissue injury. EMBO Rep. 2018;19:e45517. doi: 10.15252/embr.201745517.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201745517</ArticleId><ArticleId IdType="pmc">PMC6172460</ArticleId><ArticleId IdType="pubmed">30126923</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui T., Zia M.K., Ali S.S., Ahsan H., Khan F.H. Insight into the interactions of proteinase inhibitor- alpha-2-macroglobulin with hypochlorite. Int. J. Biol. Macromol. 2018;117:401&#x2013;406. doi: 10.1016/j.ijbiomac.2018.05.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2018.05.112</ArticleId><ArticleId IdType="pubmed">29778882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt A.R., Kumita J.R., Mifsud R.W., Gooden C.A., Wilson M.R., Dobson C.M. Hypochlorite-induced structural modifications enhance the chaperone activity of human alpha2-macroglobulin. Proc. Natl. Acad. Sci. USA. 2014;111:E2081&#x2013;E2090. doi: 10.1073/pnas.1403379111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1403379111</ArticleId><ArticleId IdType="pmc">PMC4034205</ArticleId><ArticleId IdType="pubmed">24799681</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Block G., Katz J.S., Barohn R.J., Gopalakrishnan V., Cudkowicz M., Zhang J.R., McGrath M.S., Ludington E., Appel S.H., et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol. Neuroimmunol. Neuroinflamm. 2015;2:e100. doi: 10.1212/NXI.0000000000000100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Zhang R., Block G., Katz J., Barohn R., Kasarskis E., Forshew D., Gopalakrishnan V., McGrath M.S. NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study. Amyotroph. Lateral Scler. Front. Degener. 2014;15:601&#x2013;609. doi: 10.3109/21678421.2014.951940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.951940</ArticleId><ArticleId IdType="pmc">PMC5524125</ArticleId><ArticleId IdType="pubmed">25192333</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Zhang R., Bracci P.M., Azhir A., Barohn R., Bedlack R., Benatar M., Berry J.D., Cudkowicz M., Kasarskis E.J., et al. Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses. Muscle Nerve. 2022;66:39&#x2013;49. doi: 10.1002/mus.27511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27511</ArticleId><ArticleId IdType="pmc">PMC9327716</ArticleId><ArticleId IdType="pubmed">35098554</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor. Neuron. Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Bracci P.M., Azhir A., Forrest B.D., McGrath M.S. Macrophage-Targeted Sodium Chlorite (NP001) Slows Progression of Amyotrophic Lateral Sclerosis (ALS) through Regulation of Microbial Translocation. Biomedicines. 2022;10:2907. doi: 10.3390/biomedicines10112907.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10112907</ArticleId><ArticleId IdType="pmc">PMC9687998</ArticleId><ArticleId IdType="pubmed">36428474</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Department of Health and Human Services FaDA  . Services USDoHaH. FDA; Silver Spring, MD, USA: 2019.  [(accessed on 24 September 2019)]. Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry. Available online:  www.fda.gov.</Citation></Reference><Reference><Citation>Hegazy S.H., Thomassen J.Q., Rasmussen I.J., Nordestgaard B.G., Tybjaerg-Hansen A., Frikke-Schmidt R. C-reactive protein levels and risk of dementia-Observational and genetic studies of 111,242 individuals from the general population. Alzheimers Dement. 2022;18:2262&#x2013;2271. doi: 10.1002/alz.12568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12568</ArticleId><ArticleId IdType="pmc">PMC9790296</ArticleId><ArticleId IdType="pubmed">35112776</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright F., Chan G., van Hummel A., Ittner L.M., Ke Y.D. TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Int. J. Mol. Sci. 2021;22:7781. doi: 10.3390/ijms22157781.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22157781</ArticleId><ArticleId IdType="pmc">PMC8346169</ArticleId><ArticleId IdType="pubmed">34360544</ArticleId></ArticleIdList></Reference><Reference><Citation>James B.D., Wilson R.S., Boyle P.A., Trojanowski J.Q., Bennett D.A., Schneider J.A. TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain. 2016;139:2983&#x2013;2993. doi: 10.1093/brain/aww224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww224</ArticleId><ArticleId IdType="pmc">PMC5091047</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.S., Son J., Lee D., Tsai J., Wang D., Chocron E.S., Jeong S., Kittrell P., Murchison C.F., Kennedy R.E., et al. Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset. BMC Neurol. 2022;22:62. doi: 10.1186/s12883-022-02586-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-022-02586-5</ArticleId><ArticleId IdType="pmc">PMC8862222</ArticleId><ArticleId IdType="pubmed">35189854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W., Kim S.H., Jang J.H., Kim C., Kim K., Suh Y.G., Joe Y., Chung H.T., Cha Y.-N., Surh Y.-J. Role of heme oxygenase-1 in potentiation of phagocytic activity of macrophages by taurine chloramine: Implications for the resolution of zymosan A-induced murine peritonitis. Cell. Immunol. 2018;327:36&#x2013;46. doi: 10.1016/j.cellimm.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2018.02.003</ArticleId><ArticleId IdType="pubmed">29477410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez H., Patel S.B., Pastar I. The Role of TGF&#x3b2; Signaling in Wound Epithelialization. Adv. Wound Care. 2014;3:482&#x2013;491. doi: 10.1089/wound.2013.0466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/wound.2013.0466</ArticleId><ArticleId IdType="pmc">PMC4086377</ArticleId><ArticleId IdType="pubmed">25032068</ArticleId></ArticleIdList></Reference><Reference><Citation>Schempp H., Reim M., Dornisch K., Elstner E.F. Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite-based drug WF10. Arzneimittelforschung. 2001;51:554&#x2013;562. doi: 10.1055/s-0031-1300079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0031-1300079</ArticleId><ArticleId IdType="pubmed">11505786</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X., Liu M.Y., Zhang D.F., Zhong X., Du K., Qian P., Gao H., Wei M.-J. Natural products as a potential modulator of microglial polarization in neurodegenerative diseases. Pharmacol. Res. 2019;145:104253. doi: 10.1016/j.phrs.2019.104253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.104253</ArticleId><ArticleId IdType="pubmed">31059788</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho A., Pinto S., Gromicho M., Pereira M., Swash M., de Carvalho M. Interleukin-6 and amyotrophic lateral sclerosis. J. Neurol. Sci. 2019;398:50&#x2013;53. doi: 10.1016/j.jns.2019.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.026</ArticleId><ArticleId IdType="pubmed">30682521</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S., De Carvalho M. Phrenic nerve study as outcome in clinical trials for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2021;22((Suppl. S1)):9&#x2013;13. doi: 10.1080/21678421.2021.1895842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1895842</ArticleId><ArticleId IdType="pubmed">33683161</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraci F., Spampinato S.F., Morgese M.G., Tascedda F., Salluzzo M.G., Giambirtone M.C., Caruso G., Munaf&#xf2; A., Torrisi S.A., Leggio G.M., et al. Neurobiological links between depression and AD: The role of TGF-beta1 signaling as a new pharmacological target. Pharmacol. Res. 2018;130:374&#x2013;384. doi: 10.1016/j.phrs.2018.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.02.007</ArticleId><ArticleId IdType="pubmed">29438781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyczalkowska-Tomasik A., Czarkowska-Paczek B., Zielenkiewicz M., Paczek L. Inflammatory Markers Change with Age, but do not Fall Beyond Reported Normal Ranges. Arch. Immunol. Ther. Exp. 2016;64:249&#x2013;254. doi: 10.1007/s00005-015-0357-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-015-0357-7</ArticleId><ArticleId IdType="pmc">PMC4863028</ArticleId><ArticleId IdType="pubmed">26283530</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>